Systematic review and survival meta-analysis of real world evidence on first-line pazopanib for metastatic renal cell carcinoma
Author:
Funder
Novartis
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference30 articles.
1. First-line pazopanib in non-clear cell renal carcinoma: the Italian retrospective multicenter PANORAMA study;Buti;J. Clin. Oncol.,2016
2. First-line pazopanib in non-clear-cell renal carcinoma: the Italian retrospective multicenter PANORAMA study;Buti;Clin. Genitourin. Cancer,2017
3. Pazopanib in metastatic renal cancer: a “real-world” experience at national cancer institute “Fondazione G. pascale”;Cecere;Front. Pharmacol.,2016
4. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial;Choueiri;Lancet Oncol.,2016
5. 10year outcomes from a single-centre experience of sunitinib and pazopanib as first-line treatment of metastatic renal-cell carcinoma (mRCC);Chow;J. Clin. Oncol.,2016
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pazopanib attenuated bleomycin-induced pulmonary fibrosis via suppressing TGF-β1 signaling pathway;Journal of Thoracic Disease;2024-04
2. Mathematical and Machine Learning Models of Renal Cell Carcinoma: A Review;Bioengineering;2023-11-16
3. Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study;Clinical Genitourinary Cancer;2023-11
4. Tyrosine kinase inhibitors and atherosclerosis: A close but complicated relationship;European Journal of Pharmacology;2023-09
5. Molecular Biomarkers of Prognosis in Advanced Renal Cell Carcinoma Patients Treated With Pazopanib Plus Interferon Alpha (INF-2A) in a Phase I/II Study by the Spanish Oncology Genitourinary Group;Clinical Genitourinary Cancer;2022-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3